Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target
BenzingaJul 24, 2023 08:57 ET
Galmed Pharmaceuticals Analyst Ratings
BenzingaJul 24, 2023 08:56 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Galmed Pharmaceuticals (GLMD) and Rani Therapeutics Holdings (RANI)
TipRanksJan 6, 2023 06:35 ET
Galmed Pharmaceuticals Cut to Hold From Buy by Maxim Group
Dow JonesAug 8, 2022 08:19 ET
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1 From $5
MT NewswiresAug 8, 2022 06:38 ET
H.C. Wainwright Keeps Their Hold Rating on Galmed Pharmaceuticals (GLMD)
TipRanksAug 8, 2022 06:30 ET
Galmed Pharmaceuticals Cut to Hold From Buy by Canaccord Genuity
Dow JonesAug 8, 2022 06:21 ET
Galmed Pharmaceuticals Price Target Cut to $1.00/Share From $5.00 by Canaccord Genuity
Dow JonesAug 8, 2022 06:21 ET
Galmed Pharmaceuticals analyst ratings
Benzinga Analyst RatingsAug 8, 2022 06:14 ET
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1
Benzinga Real-time NewsAug 8, 2022 06:14 ET
Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $0.70 From $5
MT NewswiresAug 4, 2022 15:42 ET
No Data
No Data